|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RWDD1 |
Gene summary for RWDD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RWDD1 | Gene ID | 51389 |
| Gene name | RWD domain containing 1 | |
| Gene Alias | CGI-24 | |
| Cytomap | 6q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | Q9H446 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51389 | RWDD1 | CA_HPV_1 | Human | Cervix | CC | 4.42e-10 | -2.94e-01 | 0.0264 |
| 51389 | RWDD1 | CCI_3 | Human | Cervix | CC | 3.18e-03 | -5.21e-01 | 0.516 |
| 51389 | RWDD1 | CCII_1 | Human | Cervix | CC | 2.41e-14 | -6.46e-01 | 0.3249 |
| 51389 | RWDD1 | T1 | Human | Cervix | CC | 6.54e-05 | -4.25e-01 | 0.0918 |
| 51389 | RWDD1 | T3 | Human | Cervix | CC | 3.02e-02 | -2.14e-01 | 0.1389 |
| 51389 | RWDD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.32e-11 | 3.64e-01 | -0.1954 |
| 51389 | RWDD1 | HTA11_83_2000001011 | Human | Colorectum | SER | 5.29e-04 | 3.41e-01 | -0.1526 |
| 51389 | RWDD1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.65e-03 | 3.30e-01 | -0.059 |
| 51389 | RWDD1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.34e-06 | 2.79e-01 | 0.0674 |
| 51389 | RWDD1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.63e-04 | 3.15e-01 | 0.281 |
| 51389 | RWDD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.77e-08 | 4.26e-01 | 0.3859 |
| 51389 | RWDD1 | AEH-subject1 | Human | Endometrium | AEH | 1.12e-18 | -4.66e-01 | -0.3059 |
| 51389 | RWDD1 | AEH-subject2 | Human | Endometrium | AEH | 2.52e-15 | -4.76e-01 | -0.2525 |
| 51389 | RWDD1 | AEH-subject3 | Human | Endometrium | AEH | 1.45e-10 | -3.46e-01 | -0.2576 |
| 51389 | RWDD1 | AEH-subject4 | Human | Endometrium | AEH | 8.41e-14 | -5.33e-01 | -0.2657 |
| 51389 | RWDD1 | AEH-subject5 | Human | Endometrium | AEH | 4.06e-05 | -4.00e-01 | -0.2953 |
| 51389 | RWDD1 | EEC-subject1 | Human | Endometrium | EEC | 3.52e-16 | -4.64e-01 | -0.2682 |
| 51389 | RWDD1 | EEC-subject2 | Human | Endometrium | EEC | 2.29e-20 | -4.90e-01 | -0.2607 |
| 51389 | RWDD1 | EEC-subject3 | Human | Endometrium | EEC | 1.23e-45 | -4.47e-01 | -0.2525 |
| 51389 | RWDD1 | EEC-subject4 | Human | Endometrium | EEC | 8.58e-11 | -3.95e-01 | -0.2571 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
| GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
| GO:000218126 | Oral cavity | EOLP | cytoplasmic translation | 102/2218 | 148/18723 | 7.91e-60 | 4.74e-56 | 102 |
| GO:000218134 | Oral cavity | NEOLP | cytoplasmic translation | 102/2005 | 148/18723 | 3.70e-64 | 2.20e-60 | 102 |
| GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
| GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
| GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
| GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
| GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RWDD1 | SNV | Missense_Mutation | novel | c.712G>A | p.Glu238Lys | p.E238K | Q9H446 | protein_coding | tolerated_low_confidence(0.31) | benign(0.01) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RWDD1 | SNV | Missense_Mutation | novel | c.463N>G | p.Lys155Glu | p.K155E | Q9H446 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RWDD1 | SNV | Missense_Mutation | novel | c.121N>A | p.Ala41Thr | p.A41T | Q9H446 | protein_coding | tolerated(0.17) | benign(0.006) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RWDD1 | SNV | Missense_Mutation | c.378G>T | p.Lys126Asn | p.K126N | Q9H446 | protein_coding | tolerated(0.09) | benign(0.02) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| RWDD1 | SNV | Missense_Mutation | novel | c.397N>A | p.Ala133Thr | p.A133T | Q9H446 | protein_coding | tolerated(0.36) | benign(0.412) | TCGA-SS-A7HO-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | PD |
| RWDD1 | SNV | Missense_Mutation | c.378N>T | p.Lys126Asn | p.K126N | Q9H446 | protein_coding | tolerated(0.09) | benign(0.02) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RWDD1 | SNV | Missense_Mutation | novel | c.331T>G | p.Leu111Val | p.L111V | Q9H446 | protein_coding | deleterious(0.01) | benign(0.117) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| RWDD1 | SNV | Missense_Mutation | c.283N>A | p.Leu95Ile | p.L95I | Q9H446 | protein_coding | tolerated(0.14) | benign(0.444) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RWDD1 | SNV | Missense_Mutation | novel | c.560N>G | p.Phe187Cys | p.F187C | Q9H446 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| RWDD1 | SNV | Missense_Mutation | novel | c.721N>C | p.Ser241Pro | p.S241P | Q9H446 | protein_coding | deleterious_low_confidence(0.01) | benign(0.123) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |